CN Patent

CN109112131B — 用于抑制alas1基因表达的组合物与方法

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2022-05-31 · 4y expired

What this patent protects

本发明涉及靶向ALAS1基因的双链核糖核酸(dsRNA)组合物，和使用这类dsRNA组合物来改变(例如，抑制)ALAS1的表达的方法。

USPTO Abstract

本发明涉及靶向ALAS1基因的双链核糖核酸(dsRNA)组合物，和使用这类dsRNA组合物来改变(例如，抑制)ALAS1的表达的方法。

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

Patent Metadata

Patent number: CN109112131B
Jurisdiction: CN
Classification: —
Expires: 2022-05-31
Drug substance claim: No
Drug product claim: No
Assignee: Icahn School of Medicine at Mount Sinai
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.